On September 29, 2026, Austin-based Tiny Health announced a $33 million oversubscribed Series B led by B Capital. Total funding is now $46 million, following a $4.5 million seed in 2021 and an $8.5 million Series A in late 2023. Existing investors Spero Ventures, The Venture City and Overwater Ventures returned. New backers include Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital senior principal Nick Whitehead joins the board.

Why It Matters

This is the second vaginal-microbiome-adjacent Series B in a matter of weeks, after Evvy's $40 million in September, alongside Juno Bio's lab build-out and Good Clean Love's founder launching a microbiome-first telehealth line. Investors are treating the vaginal and gut microbiome as diagnostic infrastructure and not as a supplement upsell. For intimate-health brands such as lube makers, probiotic sellers and pH-balanced wash lines, that raises the bar. When customers can get a sequencing report from a clinician-distributed kit, "microbiome-friendly" claims will increasingly be checked against data. The B2B growth deserves attention. A fourfold year in the provider channel suggests the business is moving from curious consumers to clinician-ordered testing, which is the route to reimbursement and to defensible pricing. The open question for the category is clinical utility. Sequencing is now cheap, but interventional evidence that acting on a report changes outcomes is still thin, which is presumably why the round pays for interventional studies.

Tiny Health sequences gut and vaginal microbiome samples from at-home kits and turns the results into reports with suggested next steps. Per Femtech Insider, the platform now serves nearly 200,000 patients and 6,000 healthcare providers. The company started with infant gut testing, built on research into the first 1,000 days of life, but adult testing now exceeds pediatric volume, and it also sells pregnancy and vaginal-microbiome tests. Founder and CEO Cheryl Sew Hoy told Crunchbase News that overall revenue has more than doubled every year and that the B2B arm, Powered by Tiny, which sells tests through clinicians and other companies, grew fourfold last year. She would not disclose revenue or valuation beyond saying the valuation is "much higher" than at the Series A.

The money will fund clinical research and interventional studies, practitioner education, the Powered by Tiny channel and a proprietary LLM called TinyAI. The company is also committing $5 million to a Microbiome Research Program that opens its testing and data to outside researchers. "This Series B round propels microbiome science as the foundational layer for the next frontier of medicine," Sew Hoy said.

Sources

Update — 2026-10-01

Initial entry — story first created.